Literature DB >> 20826425

Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity.

Pingwei Zhao1, Haleli Sharir, Ankur Kapur, Alan Cowan, Ellen B Geller, Martin W Adler, Herbert H Seltzman, Patricia H Reggio, Susanne Heynen-Genel, Michelle Sauer, Thomas D Y Chung, Yushi Bai, Wei Chen, Marc G Caron, Larry S Barak, Mary E Abood.   

Abstract

Known agonists of the orphan receptor GPR35 are kynurenic acid, zaprinast, 5-nitro-2-(3-phenylproplyamino) benzoic acid, and lysophosphatidic acids. Their relatively low affinities for GPR35 and prominent off-target effects at other pathways, however, diminish their utility for understanding GPR35 signaling and for identifying potential therapeutic uses of GPR35. In a screen of the Prestwick Library of drugs and drug-like compounds, we have found that pamoic acid is a potent GPR35 agonist. Pamoic acid is considered by the Food and Drug Administration as an inactive compound that enables long-acting formulations of numerous drugs, such as the antihelminthics oxantel pamoate and pyrantel pamoate; the psychoactive compounds hydroxyzine pamoate (Vistaril) and imipramine pamoate (Tofranil-PM); and the peptide hormones triptorelin pamoate (Trelstar) and octreotide pamoate (OncoLar). We have found that pamoic acid induces a G(i/o)-linked, GPR35-mediated increase in the phosphorylation of extracellular signal-regulated kinase 1/2, recruitment of β-arrestin2 to GPR35, and internalization of GPR35. In mice, it attenuates visceral pain perception, indicating an antinociceptive effect, possibly through GPR35 receptors. We have also identified in collaboration with the Sanford-Burnham Institute Molecular Libraries Probe Production Center new classes of GPR35 antagonist compounds, including the nanomolar potency antagonist methyl-5-[(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate (CID2745687). Pamoic acid and potent antagonists such as CID2745687 present novel opportunities for expanding the chemical space of GPR35, elucidating GPR35 pharmacology, and stimulating GPR35-associated drug development. Our results indicate that the unexpected biological functions of pamoic acid may yield potential new uses for a common drug constituent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20826425      PMCID: PMC2981393          DOI: 10.1124/mol.110.066746

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  31 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.

Authors:  Jinghong Wang; Nicole Simonavicius; Xiaosu Wu; Gayathri Swaminath; Jeff Reagan; Hui Tian; Lei Ling
Journal:  J Biol Chem       Date:  2006-06-05       Impact factor: 5.157

Review 3.  Transduction of receptor signals by beta-arrestins.

Authors:  Robert J Lefkowitz; Sudha K Shenoy
Journal:  Science       Date:  2005-04-22       Impact factor: 47.728

4.  New uses for old drugs.

Authors:  Curtis R Chong; David J Sullivan
Journal:  Nature       Date:  2007-08-09       Impact factor: 49.962

5.  Propionibacterium freudenreichii component 1.4-dihydroxy-2-naphthoic acid (DHNA) attenuates dextran sodium sulphate induced colitis by modulation of bacterial flora and lymphocyte homing.

Authors:  Y Okada; Y Tsuzuki; J Miyazaki; K Matsuzaki; R Hokari; S Komoto; S Kato; A Kawaguchi; S Nagao; K Itoh; T Watanabe; S Miura
Journal:  Gut       Date:  2005-11-18       Impact factor: 23.059

6.  Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35.

Authors:  Yasuhito Taniguchi; Hiroko Tonai-Kachi; Katsuhiro Shinjo
Journal:  FEBS Lett       Date:  2006-08-17       Impact factor: 4.124

7.  Isolation and identification of a new bifidogenic growth stimulator produced by Propionibacterium freudenreichii ET-3.

Authors:  Kakuhei Isawa; Kenichi Hojo; Nobuo Yoda; Tomonori Kamiyama; Seiya Makino; Mizue Saito; Hitomi Sugano; Chinami Mizoguchi; Saori Kurama; Mika Shibasaki; Noriko Endo; Yoshio Sato
Journal:  Biosci Biotechnol Biochem       Date:  2002-03       Impact factor: 2.043

8.  Development and validation of algorithms for measuring G-protein coupled receptor activation in cells using the LSC-based imaging cytometer platform.

Authors:  Kazuo Ozawa; Christine C Hudson; Kirsten R Wille; Sachiko Karaki; Robert H Oakley
Journal:  Cytometry A       Date:  2005-05       Impact factor: 4.355

9.  G protein-coupled receptor desensitization as a measure of signaling: modeling of arrestin recruitment to activated CCK-B receptors.

Authors:  Larry S Barak; Robert H Oakley; Michael A Shetzline
Journal:  Assay Drug Dev Technol       Date:  2003-06       Impact factor: 1.738

10.  Cloning of a G-protein-coupled receptor that shows an activity to transform NIH3T3 cells and is expressed in gastric cancer cells.

Authors:  Shun-ichiro Okumura; Hiroko Baba; Tatsuro Kumada; Koji Nanmoku; Hirofumi Nakajima; Yasushi Nakane; Koshiro Hioki; Kazuhiro Ikenaka
Journal:  Cancer Sci       Date:  2004-02       Impact factor: 6.716

View more
  46 in total

1.  Crucial positively charged residues for ligand activation of the GPR35 receptor.

Authors:  Pingwei Zhao; Tom R Lane; Helen G L Gao; Dow P Hurst; Evangelia Kotsikorou; Long Le; Eugen Brailoiu; Patricia H Reggio; Mary E Abood
Journal:  J Biol Chem       Date:  2013-12-17       Impact factor: 5.157

Review 2.  Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.

Authors:  Bryan L Roth; Wesley K Kroeze
Journal:  J Biol Chem       Date:  2015-06-22       Impact factor: 5.157

Review 3.  Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.

Authors:  Edson X Albuquerque; Robert Schwarcz
Journal:  Biochem Pharmacol       Date:  2012-12-25       Impact factor: 5.858

4.  High-throughput identification and characterization of novel, species-selective GPR35 agonists.

Authors:  Zaynab Neetoo-Isseljee; Amanda E MacKenzie; Craig Southern; Jeff Jerman; Edward G McIver; Nicholas Harries; Debra L Taylor; Graeme Milligan
Journal:  J Pharmacol Exp Ther       Date:  2012-12-21       Impact factor: 4.030

5.  The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35.

Authors:  Amanda E MacKenzie; Gianluigi Caltabiano; Toby C Kent; Laura Jenkins; Jennifer E McCallum; Brian D Hudson; Stuart A Nicklin; Lindsay Fawcett; Rachel Markwick; Steven J Charlton; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2013-10-10       Impact factor: 4.436

6.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 7.  Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery.

Authors:  Flavio Moroni; Andrea Cozzi; Maria Sili; Guido Mannaioni
Journal:  J Neural Transm (Vienna)       Date:  2012-01-04       Impact factor: 3.575

8.  Identification of Crucial Amino Acid Residues Involved in Agonist Signaling at the GPR55 Receptor.

Authors:  Mary A Lingerfelt; Pingwei Zhao; Haleli P Sharir; Dow P Hurst; Patricia H Reggio; Mary E Abood
Journal:  Biochemistry       Date:  2017-01-11       Impact factor: 3.162

9.  Structure-activity relationships of benzothiazole GPR35 antagonists.

Authors:  Manahil M Abdalhameed; Pingwei Zhao; Dow P Hurst; Patricia H Reggio; Mary E Abood; Mitchell P Croatt
Journal:  Bioorg Med Chem Lett       Date:  2016-12-05       Impact factor: 2.823

10.  GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17?

Authors:  Soo-Jin Park; Seung-Jin Lee; So-Yeon Nam; Dong-Soon Im
Journal:  Br J Pharmacol       Date:  2017-12-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.